Drug · DIN 02438364
SYNAGIS
1 ML SINGLE-USE VIAL
Authorized, but not sold for a year or more
Authorized, but the company reports it has not been sold in Canada for at least 12 months.
Status Dormant since March 19, 2026; first marketed November 3, 2016.
- Drug Identification Number (DIN)
- 02438364
- Company (DIN owner)
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Intramuscular
- Therapeutic class (ATC)
- Palivizumab J06BD01
- Class
- Human
- Record last updated
- August 19, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PALIVIZUMAB | 100 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 9, 2021: NOC 26262New Drug Submission (NDS) · Change of Product Ownership (DIN)
- March 6, 2015: NOC 16658Supplement to a New Drug Submission (SNDS) · New formulation
Other DINs named SYNAGIS
- DIN 02245889 · Cancelled Post Market
- DIN 02245890 · Cancelled Post Market
- DIN 02438372 · Dormant